Graham Baker

Chief Financial Officer · Jardine Matheson

Diversified investments

Graham Baker is chief financial officer of Jardine Matheson. He joined in 2020 after serving as a chief financial officer in medical technology and generic pharmaceuticals.

Last reviewed: Nov 19, 2026

Executive Summary

Graham Baker is chief financial officer of Jardine Matheson. He joined in 2020 after serving as a chief financial officer in medical technology and generic pharmaceuticals.

Career Highlights

  • Worked for 20 years at AstraZeneca in roles spanning the U.K., Japan and Singapore.
  • Was CFO at Alvogen and served as an executive director and CFO at Smith+Nephew from 2017 to 2020.
  • Helped simplify Jardines’ holding structure through the 2021 privatization of Jardine Strategic.

Professional Journey

Baker spent two decades at AstraZeneca in roles in the United Kingdom and abroad, including Japan and Singapore. He later became chief financial officer of Alvogen, which makes generic pharmaceuticals. In 2017 he joined Smith+Nephew as chief financial officer and an executive director.

Baker moved to Jardine Matheson in 2020 as group finance director. One of his early assignments was the group’s simplification of its ownership structure, beginning with the privatization of Jardine Strategic in 2021. The change was part of a wider shift toward a simpler investment holding company.

His later work included transactions to release capital for other investments and changes in shareholder engagement. He also represented Jardines on the boards of DFI Retail and I-MED Radiology Network and worked with finance leaders across the portfolio on a development program. On November 17, 2026 Jardines announced that he plans to hand over the CFO role in the second quarter of 2027; he remains in the position.

Education

MA in Economics, University of Cambridge. Chartered Accountant and Chartered Tax Adviser.